Advances in blood–brain barrier modeling in microphysiological systems highlight critical differences in opioid transport due to cortisol exposure
暂无分享,去创建一个
J. Wikswo | K. Hillgren | E. Lippmann | Jacquelyn A. Brown | S. Faley | G. Sawada | Yajuan Shi | Thomas K. Baker
[1] N. Voelcker,et al. Advances in Microfluidic Blood-Brain Barrier (BBB) Models. , 2019, Trends in biotechnology.
[2] Sean P. Palecek,et al. An isogenic neurovascular unit model comprised of human induced pluripotent stem cell-derived brain microvascular endothelial cells, pericytes, astrocytes, and neurons , 2019, Fluids and Barriers of the CNS.
[3] Sean P. Palecek,et al. Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies , 2019, Nature Communications.
[4] Kylie M. Balotin,et al. A Simplified, Fully Defined Differentiation Scheme for Producing Blood-Brain Barrier Endothelial Cells from Human iPSCs , 2019, Stem cell reports.
[5] S. Hwang,et al. Effects of surgery start time on postoperative cortisol, inflammatory cytokines, and postoperative hospital day in hip surgery , 2019, Medicine.
[6] A. Sehgal,et al. Endocytosis at the Drosophila blood–brain barrier as a function for sleep , 2018, eLife.
[7] Sean P Sheehy,et al. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic coupling of endothelial and neuronal cells , 2018, Nature Biotechnology.
[8] A. Sehgal,et al. A Circadian Clock in the Blood-Brain Barrier Regulates Xenobiotic Efflux , 2018, Cell.
[9] U. Pirunsan,et al. Immediate Effects of Core Stabilization Exercise on &bgr;‐Endorphin and Cortisol Levels Among Patients With Chronic Nonspecific Low Back Pain: A Randomized Crossover Design , 2018, Journal of manipulative and physiological therapeutics.
[10] Koji Ando,et al. A molecular atlas of cell types and zonation in the brain vasculature , 2018, Nature.
[11] M. Tome,et al. The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse , 2017, Fluids and Barriers of the CNS.
[12] M. Morris,et al. SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers , 2017, The AAPS Journal.
[13] E. Lippmann,et al. Accelerated differentiation of human induced pluripotent stem cells to blood–brain barrier endothelial cells , 2017, Fluids and Barriers of the CNS.
[14] Orlando S. Hoilett,et al. Metabolic consequences of inflammatory disruption of the blood-brain barrier in an organ-on-chip model of the human neurovascular unit , 2016, Journal of Neuroinflammation.
[15] Qing Yang,et al. Recreating blood-brain barrier physiology and structure on chip: A novel neurovascular microfluidic bioreactor. , 2015, Biomicrofluidics.
[16] H. Oster,et al. Circadian Clocks and the Interaction between Stress Axis and Adipose Function , 2015, International journal of endocrinology.
[17] Alf Lamprecht,et al. Coadministration of P-Glycoprotein Modulators on Loperamide Pharmacokinetics and Brain Distribution , 2014, Drug Metabolism and Disposition.
[18] Sean P. Palecek,et al. A retinoic acid-enhanced, multicellular human blood-brain barrier model derived from stem cell sources , 2014, Scientific Reports.
[19] Alon Friedman,et al. Overview and introduction: The blood–brain barrier in health and disease , 2012, Epilepsia.
[20] Sean P. Palecek,et al. Human Blood-Brain Barrier Endothelial Cells Derived from Pluripotent Stem Cells , 2012, Nature Biotechnology.
[21] E. Bruera,et al. Association between serum cortisol and testosterone levels, opioid therapy, and symptom distress in patients with advanced cancer. , 2011, Journal of pain and symptom management.
[22] Nicolas Tournier,et al. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). , 2010, The international journal of neuropsychopharmacology.
[23] David S. Miller,et al. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. , 2010, Trends in pharmacological sciences.
[24] Thomas J. Raub,et al. Rhodamine inhibitors of P-glycoprotein: an amide/thioamide "switch" for ATPase activity. , 2009, Journal of medicinal chemistry.
[25] C. Pariante,et al. A revised role for P-glycoprotein in the brain distribution of dexamethasone, cortisol, and corticosterone in wild-type and ABCB1A/B-deficient mice. , 2008, Endocrinology.
[26] T. Terasaki,et al. Involvement of the Pyrilamine Transporter, a Putative Organic Cation Transporter, in Blood-Brain Barrier Transport of Oxycodone , 2008, Drug Metabolism and Disposition.
[27] Eric V Shusta,et al. In vitro models of the blood–brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[28] T. Terasaki,et al. A functional in vitro model of rat blood–brain barrier for molecular analysis of efflux transporters , 2007, Brain Research.
[29] U. Simonsson,et al. In Vivo Blood-Brain Barrier Transport of Oxycodone in the Rat: Indications for Active Influx and Implications for Pharmacokinetics/Pharmacodynamics , 2006, Drug Metabolism and Disposition.
[30] Helga E de Vries,et al. Puromycin‐purified rat brain microvascular endothelial cell cultures exhibit improved barrier properties in response to glucocorticoid induction , 2006, Journal of neurochemistry.
[31] H. Galla,et al. Murine brain capillary endothelial cells exhibit improved barrier properties under the influence of hydrocortisone , 2005, Brain Research.
[32] T. Davis,et al. The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.
[33] U. Simonsson,et al. Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. , 2005, Journal of pharmaceutical sciences.
[34] G. Fricker,et al. Modulation of Drug Transporters at the Blood-Brain Barrier , 2004, Pharmacology.
[35] P. Jenner,et al. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates , 2004, Movement disorders : official journal of the Movement Disorder Society.
[36] J. Temsamani,et al. Evidence for an active transport of morphine‐6‐β‐d‐glucuronide but not P‐glycoprotein‐mediated at the blood–brain barrier , 2003, Journal of neurochemistry.
[37] R. Kim,et al. Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux Drug Transporter P-glycoprotein , 2002, Anesthesiology.
[38] R. Egleton,et al. Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier , 2001, Trends in Neurosciences.
[39] R Hori,et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. , 1992, The Journal of biological chemistry.
[40] A. Butt,et al. Calcium-dependent regulation of potassium permeability in the glial perineurium (blood-brain barrier) of the crayfish , 1990, Neuroscience.
[41] Thomas S. Reese,et al. FINE STRUCTURAL LOCALIZATION OF A BLOOD-BRAIN BARRIER TO EXOGENOUS PEROXIDASE , 1967, The Journal of cell biology.
[42] Eve M. Taylor,et al. The Impact of Efflux Transporters in the Brain on the Development of Drugs for CNS Disorders , 2002, Clinical pharmacokinetics.
[43] M. Brightman,et al. Nonpermeable and permeable vessels of the brain. , 1992, NIDA research monograph.